Cellenkos
Cellenkos is a clinical-stage biotechnology company focused on developing allogeneic, tissue-targeted, immune T-regulatory cell therapies to treat autoimmune diseases and inflammatory disorders. Founded in 2016, it leverages proprietary cord blood-derived Treg technology to create off-the-shelf cell-based products aimed at restoring immune balance and treating a wide spectrum of inflammatory conditions.
Industries
Nr. of Employees
small (1-50)
Products
Allogeneic cord blood–derived regulatory T-cell therapy for bone marrow failure
Cryopreserved, off-the-shelf regulatory T-cell product derived from umbilical cord blood designed to home to bone marrow and suppress pathogenic cytotoxic T cells in bone marrow failure syndromes.
Cryopreserved cord blood–derived regulatory T-cell therapy for COVID-19 ARDS
Randomized, double-blind, placebo-controlled cryopreserved Treg infusion product evaluated for safety and early efficacy in COVID-19–induced ARDS.
CXCR4-enriched cord blood–derived regulatory T-cell therapy as add-on for myelofibrosis
A CXCR4-enriched, cryopreserved regulatory T-cell product developed for use as an add-on therapy to JAK inhibitor treatment in patients with myelofibrosis who have suboptimal response.
Neurotropic cord blood–derived regulatory T-cell therapy for neuroinflammatory disease (ALS)
Neurotropic, CNS-homing regulatory T-cell product in cryopreserved, off-the-shelf format developed for safety and preliminary efficacy evaluation in amyotrophic lateral sclerosis.
Allogeneic cord blood–derived regulatory T-cell therapy for bone marrow failure
Cryopreserved, off-the-shelf regulatory T-cell product derived from umbilical cord blood designed to home to bone marrow and suppress pathogenic cytotoxic T cells in bone marrow failure syndromes.
Cryopreserved cord blood–derived regulatory T-cell therapy for COVID-19 ARDS
Randomized, double-blind, placebo-controlled cryopreserved Treg infusion product evaluated for safety and early efficacy in COVID-19–induced ARDS.
CXCR4-enriched cord blood–derived regulatory T-cell therapy as add-on for myelofibrosis
A CXCR4-enriched, cryopreserved regulatory T-cell product developed for use as an add-on therapy to JAK inhibitor treatment in patients with myelofibrosis who have suboptimal response.
Neurotropic cord blood–derived regulatory T-cell therapy for neuroinflammatory disease (ALS)
Neurotropic, CNS-homing regulatory T-cell product in cryopreserved, off-the-shelf format developed for safety and preliminary efficacy evaluation in amyotrophic lateral sclerosis.
Services
cGMP cell therapy manufacturing and process development
On-site manufacturing, technology transfer, process development and scale-up for allogeneic cell therapy products with cryopreservation capabilities.
Clinical development and trial execution support
Design and conduct of early-phase clinical trials including Phase 1 safety runs, Phase 1b open-label studies and randomized, double-blind, placebo-controlled trials.
Sponsored research and academic collaboration
Sponsored research agreements and joint translational studies with academic medical centers to evaluate clinical applications of cell therapy products.
Temperature-controlled logistics for cell therapy shipments
Provisioning and coordination of temperature-controlled, on-demand logistics solutions for cryopreserved cell therapy distribution to clinical sites and patients.
cGMP cell therapy manufacturing and process development
On-site manufacturing, technology transfer, process development and scale-up for allogeneic cell therapy products with cryopreservation capabilities.
Clinical development and trial execution support
Design and conduct of early-phase clinical trials including Phase 1 safety runs, Phase 1b open-label studies and randomized, double-blind, placebo-controlled trials.
Sponsored research and academic collaboration
Sponsored research agreements and joint translational studies with academic medical centers to evaluate clinical applications of cell therapy products.
Temperature-controlled logistics for cell therapy shipments
Provisioning and coordination of temperature-controlled, on-demand logistics solutions for cryopreserved cell therapy distribution to clinical sites and patients.
Expertise Areas
- Allogeneic cell therapy development
- cGMP cell manufacturing and scale-up
- Clinical trial design and execution for cell therapies
- Regulatory submissions and IND-enabling activities
Key Technologies
- Cord blood–derived regulatory T cells
- Cell enrichment and activation platforms
- CXCR4-mediated homing enrichment
- Neurotropic/tissue-targeting cell modification